Search results for "Viremia"

showing 10 items of 66 documents

Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infecti…

1994

A 48-year-old male patient was admitted with acquired immunodeficiency syndrome (stage III, Centers for Disease Control 1993) and viremic hepatitis B. Blood CD4 count was 15/microliters. Discontinuation of prednisolone, previously prescribed by the patient's family practitioner because of elevated liver enzymes, resulted in severe hepatitis (alanine aminotransferase > 300U/l). Administration of interferon-alpha (9 x 10(6) U s.c. 3 x weekly) was initiated. Serum markers of viral replication disappeared, and aminotransferase levels returned to normal within a few weeks. The patient's serum was found negative for HBsAg after 3 months. Immunohistochemical analysis of liver biopsies before and d…

MaleHepatitis B virusHBsAgAlpha interferonmedicine.disease_causeDrug DiscoverymedicineHumansViremiaSeroconversionGenetics (clinical)Interferon alfaHepatitis B virusAIDS-Related Opportunistic Infectionsbusiness.industryInterferon-alphaGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseChronic DiseaseImmunologyPrednisoloneMolecular MedicineViral diseasebusinessmedicine.drugThe Clinical Investigator
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation

2018

Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by…

Malebasic (laboratory) research/science0301 basic medicinemedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationGastroenterologyOrgan transplantation0302 clinical medicineRisk FactorsImmunology and AllergyPharmacology (medical)Whole bloodIncidenceHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedPrognosissurgical procedures operativeCytomegalovirus Infectionscytomegalovirus (CMV) [infection and infectious agents-viral]Femaleantiviral [antibiotic]pharmacokinetics/pharmacodynamicsImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtyinfectious diseasesirolimus [immunosuppressant-mechanistic target of rapamycin]clinical research/practicetacrolimus [immunosuppressant-calcineurin inhibitor]03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousTrough ConcentrationViremiabone marrow/hematopoietic stem cell transplantationAgedSirolimusTransplantationbusiness.industryTransplant RecipientsTacrolimus030104 developmental biologySpainRelative riskSirolimusDNA ViralpharmacologybusinessSerostatusFollow-Up Studies030215 immunology
researchProduct

Análisis de resultados del Programa de Control de Calidad Externo de carga viral del VIH-1, del VHC y del VHB. Año 2013

2015

Human immunodeficiency virus type 1 (HIV-1) and hepatitis B (HBV) and C virus (HCV) viral load determinations are among the most relevant markers for the follow up of patients infected with these viruses. External quality control tools are crucial to ensure the accuracy of results obtained by microbiology laboratories. This article summarized the results obtained from the 2013 SEIMC External Quality Control Programme for HIV-1, HCV, and HBV viral loads. In the HIV-1 program, a total of five standards were sent. One standard consisted in seronegative human plasma, while the remaining four contained plasma from three different viremic patients, in the range of 2-5 log10 copies/mL; two of thes…

Microbiology (medical)Hepatitis B virusmedicine.medical_specialtybiologybusiness.industryHepacivirusViremiaRepeatabilityHepatitis CHepatitis Bmedicine.disease_causemedicine.diseasebiology.organism_classificationVirologyInternal medicineMedicineLaboratory Proficiency TestingbusinessViral loadEnfermedades Infecciosas y Microbiología Clínica
researchProduct

Performance of the COBAS AMPLICOR HCV MONITOR Test, Version 2.0, an Automated Reverse Transcription-PCR Quantitative System for Hepatitis C Virus Loa…

2000

ABSTRACT A clinical evaluation of an automated quantitative PCR assay, the COBAS AMPLICOR HCV MONITOR test, version 2.0 (v2.0), was carried out to assess the performance of this test in comparison with that of the previous, manual version, the AMPLICOR HCV MONITOR test, and with that of nested PCR. Serial dilutions of serum samples infected with genotype 1b, 2a, or 3, as well as synthetic RNA transcripts and serum samples derived from 87 patients with chronic hepatitis C and infected with genotype 1a, 1b, 2a, 2b, 3a, 3b, 4, or 5, were analyzed to determine the ability of the system to efficiently quantify various hepatitis C virus (HCV) genotypes. These experiments showed that the COBAS AMP…

Microbiology (medical)Serial dilutionHepacivirusHepatitis C virusViremiaHepacivirusmedicine.disease_causePolymerase Chain ReactionFlaviviridaeVirologymedicineHumansbiologyReverse Transcriptase Polymerase Chain Reactionvirus diseasesReproducibility of ResultsHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseaseVirologyImmunologyRNA ViralReagent Kits DiagnosticNested polymerase chain reactionViral loadJournal of Clinical Microbiology
researchProduct

Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigationa…

2018

Microbiology (medical)business.industrymedicine.medical_treatmentCongenital cytomegalovirus infectionViremiaHematopoietic stem cell transplantation030230 surgerymedicine.disease03 medical and health sciences0302 clinical medicineInfectious DiseasesImmunologymedicinebusiness030215 immunology
researchProduct

Adoptive CD8 T Cell Control of Pathogens Cannot Be Improved by Combining Protective Epitope Specificities

2008

Adoptive transfer of CD8 T cells has the potential to cure infectious or malignant diseases that are refractory to conventional chemotherapy. A practically important but still unanswered question is whether mixtures of protective CD8 T cells with different epitope specificities mediate more efficient effector cell functions than do the monospecific individual CD8 T cell populations. In this study, we have addressed this issue for models of viral and bacterial infection. CD8 T cell-mediated cytotoxicity in vitro and protection in vivo were assessed to test whether CD8 T cell lines cooperate in target cell lysis and control of infection, respectively. Our data clearly show that mixtures of cy…

MuromegalovirusAdoptive cell transferT cellEpitopes T-LymphocyteBacteremiaStreptamerCD8-Positive T-LymphocytesBiologyEpitopeMicemedicineAnimalsImmunology and AllergyCytotoxic T cellViremiaAntigen-presenting cellT lymphocyteAdoptive TransferListeria monocytogenesVirologyDisease Models AnimalInfectious Diseasesmedicine.anatomical_structureCytomegalovirus InfectionsImmunologyFemaleCD8The Journal of Infectious Diseases
researchProduct

Association of human herpesvirus 6 and human herpesvirus 7 with demyelinating diseases of the nervous system.

2001

Peripheral blood mononuclear cells and plasma of 113 patients with neurological disorders and 150 blood donors were analyzed for HHV-6 and HHV-7 sequences by PCR. The prevalence of HHV-6 was significantly higher in patients with multiple sclerosis (P < 0.01) than in cases of nondemyelinating diseases of the central and demyelinating diseases of the peripheral nervous systems and blood donors. HHV-6 viremia was found only in patients with multiple sclerosis, predominantly in the active phase of the disease. A significantly higher frequency of HHV-7 reactivation in patients with demyelinating diseases of the peripheral nervous system suggests also its association with demyelinating processes.

Nervous systemAdultMalemedicine.medical_specialtyNeurologyMultiple SclerosisAdolescentvirusesHerpesvirus 6 HumanRoseolovirus InfectionsViremiaHerpesvirus 7 HumanDiseasePeripheral blood mononuclear cellPolymerase Chain ReactionCellular and Molecular NeuroscienceVirologyPrevalenceMedicineHumansViremiaAgedBrain Diseasesbiologybusiness.industryMultiple sclerosisvirus diseasesMiddle Agedmedicine.diseasebiology.organism_classificationmedicine.anatomical_structureNeurologyPeripheral nervous systemImmunologyDNA ViralHuman herpesvirus 6FemaleNeurology (clinical)businessJournal of neurovirology
researchProduct

Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction

2002

Background and Objectives Transmission of human parvovirus B19 (PV B19) by transfusion of blood and blood products is well documented. Although PV B19 infection is connected with severe complications in some recipients, donor screening is not yet mandatory. In this study the prevalence of PV B19, as detected by a haemagglutination assay (the Human PV B19 Antigen-Test), was assessed. In addition, the persistence of B19 DNA and the serological status of blood donors was also assessed. The specificity and utility of the Human PV B19 Antigen-Test for donor screening was investigated and compared with other screening strategies. Materials and Methods The prevalence of PV B19 viraemia was assesse…

ParvoviridaeHemagglutination assaybiologyHemagglutinationvirusesvirus diseasesViremiaHematologyGeneral Medicinebiology.organism_classificationmedicine.diseaseVirologylaw.inventionSerologylawhemic and lymphatic diseasesImmunologybiology.proteinmedicineViral diseaseNeutralizing antibodyPolymerase chain reactionVox Sanguinis
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct